Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07311993 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
A Phase 1 study of Breast Cancer, sponsored by Cellectar Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT07311993 is a Phase 1 study of Breast Cancer that is actively recruiting participants, run by Cellectar Biosciences. The registered enrollment target is 60 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07311993, a Phase 1 study of Breast Cancer, is actively recruiting participants, sponsored by Cellectar Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the safety and efficacy of 3 different dose levels of CLR 125 in patients with advanced triple negative breast cancer. The main questions the study aims to answer are: * What dose and regimen should be used in future trials of CLR 125 in patients with advanced triple negative breast cancer. * What side effects do participants have when taking CLR 125. Participants will: * Have CLR 125 administered via infusion 4 times each cycle; repeated every 8 weeks. * Visit the clinic once every 3 weeks for checkups and testing. * Report any side effects or new medications. Some participants may also receive one dose of CLR 131 to evaluate the amount of radiation delivered to various organs and to the tumor. These participants will: * Have 4 scans completed over 2 weeks * Have blood drawn 6 times over 2 weeks.
Conditions Studied
Interventions
- DRUG Iopofosine I 131
- DRUG CLR 125
Study Locations (2)
Florida
- Mayo Clinic Florida - Jacksonville
Maryland
- United Theranostics - Glen Burnie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-12-05 |
| Est. Completion | 2029-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07311993
The ClinicalTrials.gov registry entry for NCT07311993 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Cellectar Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Iopofosine I 131 is the first listed.
NCT07311993 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT07311993 about?
NCT07311993 is a clinical study titled "Phase 1 Study of CLR 125 in Triple Negative Breast Cancer". The goal of this clinical trial is to evaluate the safety and efficacy of 3 different dose levels of CLR 125 in patients with advanced triple negative breast cancer. The main questions the study aims to answer are: * What dose and regimen should be used in future trials of CLR 125 in patients with ...
What is the current status of trial NCT07311993?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-12-05. Estimated completion is 2029-07.
What conditions does trial NCT07311993 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT07311993?
The interventions under investigation include: Iopofosine I 131 (DRUG), CLR 125 (DRUG).
Who is sponsoring clinical trial NCT07311993?
This trial is sponsored by Cellectar Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07311993 being conducted?
This trial has 2 study locations across Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.